CoChat
Sign Up
Cited by 106Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and TreatmentMRI in cancer diagnosis

The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions

Open access
Nascimento, Duarte, Suchard, Guilherme, Hatem, Maruan, de Abreu, Armando·2014·Insights into Imaging
DOI 10.1007/s13244-014-0339-zPMC PMC4141345
Open this paper in CoChat — free account

Abstract

UNLABELLED: Bone tumours and tumour-like lesions are frequently encountered by radiologists. Although radiographs are the primary screening technique, magnetic resonance imaging (MRI) can help narrow the differential or make a specific diagnosis when a lesion is indeterminate or shows signs of aggressiveness. MRI can extend the diagnostic evaluation by demonstrating several tissue components. Even when a specific diagnosis cannot be made, the differential diagnosis can be narrowed. MRI is superior to the other imaging modalities in detecting bone marrow lesions and tumoral tissue (faint lytic/sclerotic bone lesions can be difficult to visualise using only radiographs). Contrast-enhanced MRI can reveal the most vascularised parts of the tumour and MRI guidance makes it possible to avoid biopsing necrotic areas. MRI is very helpful in local staging and surgical planning by assessing the degree of intramedullary extension and invasion of the adjacent physeal plates, joints, muscle compartments and neurovascular bundles. It can be used in assessing response to neoadjuvant therapy and further restaging. The post-therapeutic follow-up should also be done using MRI. Despite the high quality of MRI, there are a few pitfalls and limitations of which one should be aware. Applications of MRI in bone tumours will probably continue to grow as new sequences are further studied. TEACHING POINTS: • When a lesion is indeterminate or shows signs of aggressiveness, MRI is indicated. • When MRI does not lead to a diagnosis, biopsy is indicated. • MRI is superior to the other imaging modalities in detecting bone marrow lesions. • MRI is very helpful in local staging and surgical planning. • MRI is used in assessing the response to neoadjuvant therapy, restaging and post-therapeutic follow-up.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13244-014-0339-z

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MRI is a medical imaging modality that allows for the evaluation of soft-tissue diseases and the assessment of bone quality.

    “Magnetic Resonance Imaging (MRI) is a medical imaging modality that allows for the evaluation of soft-tissue diseases and the assessment of bone quality.”

    From Towards 2D/3D Registration of the Preoperative MRI to Intraoperative Fluoroscopic Images for Visualisation of Bone Defects (2023) · cites this paper as Nascimento et al. 2014

    In “Applying MRI in tumour detection and diagnosis” (page unavailable), the paper says MRI can demonstrate soft-tissue pathology associated with osteochondromas. The Introduction and tumour-detection section also describe MRI’s ability to characterise bone and bone-marrow lesions, but they do not establish that it assesses bone quality. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 44

  1. [2]Ojala R Sequeiros RB Klemola R Vahala E Jyrkinen L Tervonen O MR-guided bone biopsy: preliminary report of a new guiding method J Magn Reson Imaging 2002 15 1 82 86 10.1002/jmri.10041 11793461 · DOI
  2. [3]Ribeiro MB Oliveira CR Filippi RZ Estudo histopatológico do trajeto de biópsia de tumores musculoesqueléticos malignos Acta Ortopédica Brasileira 2009 17 5 279 281 10.1590/S1413-78522009000500005 · DOI
  3. [4]Davies AM Sundaram M James SLJ Imaging of Bone Tumors and Tumor-Like Lesions (Techniques and Applications) 2009 Berlin Heidelberg Springer
  4. [5]Erly WK Oh ES Outwater EK The utility of in-phase/opposed-phase imaging in differentiating malignancy from acute benign compression fractures of the spine AJNR Am J Neuroradiol 2006 27 6 1183 1188 16775260 PMC8133913
  5. [6]Disler DG McCauley TR Ratner LM Kesack CD Cooper JA In-phase and out-of-phase MR imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water AJR Am J Roentgenol 1997 169 5 1439 1447 10.2214/ajr.169.5.9353477 9353477 · DOI
  6. [7]Berquist TH Magnetic resonance imaging of primary skeletal neoplasms Radiol Clin North Am 1993 31 2 411 24 8446757
  7. [8]Hayashida Y Yakushiji T Awai K Monitoring therapeutic response of primary bone tumors by diffusion weighted image: initial results Eur Radiol 2006 16 12 2637 2643 10.1007/s00330-006-0342-y 16909220 · DOI
  8. [9]Bley TA Wieben O Uhl M Diffusion-weighted MR imaging in musculoskeletal radiology: applications in trauma, tumors, and inflammation Magn Reson Imaging Clin N Am 2009 17 2 263 275 10.1016/j.mric.2009.01.005 19406358 · DOI
  9. [10]American College of Radiology (2011) ACR Appropriateness Criteria. Follow-up of Malignant or Aggressive Musculoskeletal Tumors. Available via http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/FollowupMalignantOrAggressiveMusculoskeletalTumors.pdf. Accessed 9 Apr 2014 26922595
  10. [11]Wang CK Li CW Hsieh TJ Chien SH Liu GC Tsai KB Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results Radiology 2004 232 2 599 605 10.1148/radiol.2322031441 15286325 · DOI
  11. [12]May DA Good RB Smith DK Parsons TW MR imaging of musculoskeletal tumors and tumor mimickers with intravenous gadolinium: experience with 242 patients Skeletal Radiol 1997 26 1 2 15 10.1007/s002560050183 9040136 · DOI
  12. [13]Zimmer WD Berquist TH McLeod RA Bone tumors: magnetic resonance imaging versus computed tomography Radiology 1985 155 3 709 718 10.1148/radiology.155.3.4001374 4001374 · DOI
  13. [14]Simpfendorfer CS Ilaslan H Davies AM James SL Obuchowski NA Sundaram M Does the presence of focal normal marrow fat signal within a tumor on MRI exclude malignancy? An analysis of 184 histologically proven tumors of the pelvic and appendicular skeleton Skeletal Radiol 2008 37 9 797 804 10.1007/s00256-008-0523-7 18551289 · DOI
  14. [15]Morrison WB Sanders TG Problem Solving Musculoskeletal Imaging 2008 1 Philadelphia Mosby Elsevier 251 324
  15. [16]Greenspan A (2011) Orthopedic imaging: a practical approach, 5th edn. Lippincott Williams & Wilkins
  16. [17]Alyas F James SL Davies AM Saifuddin A The role of MR imaging in the diagnostic characterization of appendicular bone tumours and tumour-like conditions Eur Radiol 2007 17 2675 86 10.1007/s00330-007-0597-y 17342487 · DOI
  17. [18]Woertler K Lindner N Gosheger G Brinkschmidt C Heindel W Osteochondroma: MR imaging of tumor-related complications Eur Radiol 2000 10 5 832 840 10.1007/s003300051014 10823643 · DOI
  18. [20]Alyas F Saifuddin A Fluid-fluid levels in bone neoplasms: variation of T1-weighted signal intensity of the superior to inferior layers—diagnostic significance on magnetic resonance imaging Eur Radiol 2008 18 2642 2651 10.1007/s00330-008-1060-4 18546000 · DOI
  19. [21]Van Dyck P Vanhoenacker FM Vogel J Prevalence, extension and characteristics of fluid-fluid levels in bone and soft tissue tumors Eur Radiol 2006 16 12 2644 51 10.1007/s00330-006-0250-1 16612549 · DOI
  20. [22]Murphey MD Wan Jaovisidha S Temple HT Gannon FH Jelinek JS Malawer MM Telangiectatic osteosarcoma: radiologic-pathologic comparison Radiology 2003 229 2 545 553 10.1148/radiol.2292021130 14512511 · DOI
  21. [23]Jee WH Park YK McCauley TR Chondroblastoma: MR characteristics with pathologic correlation J Comput Assist Tomogr 1999 23 5 721 726 10.1097/00004728-199909000-00016 10524855 · DOI
  22. [24]Daldrup-Link HE Henning T Link TM MR imaging of therapy-induced changes of bone marrow Eur Radiol 2007 17 3 743 761 10.1007/s00330-006-0404-1 17021706 PMC1797072 · DOI
  23. [25]Tamburrini O Cova MA Console D Martingano P The evolving role of MRI in oncohaematological disorders Radiol Med 2007 112 5 703 21 10.1007/s11547-007-0174-0 17653627 · DOI
  24. [26]Narquin S Ingrand P Azais I Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma Diagn Interv Imaging 2013 94 6 629 36 10.1016/j.diii.2013.01.005 23683788 · DOI
  25. [27]Schirrmeister H Bommer M Buck AK Initial results in the assessment of multiple myeloma using 18 F-FDG PET Eur J Nucl Med Mol Imaging 2002 29 3 361 6 10.1007/s00259-001-0711-3 12002711 · DOI
  26. [28]Lecouvet FE Malghem J Michaux L Skeletal survey In advanced multiple myeloma: radiographic versus MR imaging survey Br J Haematol 1999 106 35 39 10.1046/j.1365-2141.1999.01529.x 10444160 · DOI
  27. [29]Durie BG Kyle RA Belch A Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation Hematol J 2003 4 6 379 398 10.1038/sj.thj.6200312 14671610 · DOI
  28. [30]Walker R Barlogie B Haessler J Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications J Clin Oncol 2007 25 1121 1128 10.1200/JCO.2006.08.5803 17296972 · DOI
  29. [31]Dimopoulos M Terpos E Comenzo RL International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma Leukemia 2009 23 9 1545 1556 10.1038/leu.2009.89 19421229 · DOI
  30. [32]Rajkumar SV MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management Hematology Am Soc Hematol Educ Program 2005 1 340 3455 10.1182/asheducation-2005.1.340 16304401 · DOI
  31. [33]Lecouvet FE Vande Berg BC Michaux L Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging Radiology 1998 209 3 653 60 10.1148/radiology.209.3.9844655 9844655 · DOI
  32. [34]Dutoit JC Vanderkerken MA Verstraete KL Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma Eur J Radiol 2013 82 9 1444 52 10.1016/j.ejrad.2013.04.012 23726124 · DOI
  33. [35]Hogeboom WR Hoekstra HJ Mooyaart EL MRI or CT in the preoperative diagnosis of bone tumours Eur J Surg Oncol 1992 18 1 67 72 1737596
  34. [36]Sajadi KR Heck RK Neel MD The incidence and prognosis of osteosarcoma skip metastases Clin Orthop Relat Res 2004 426 92 96 10.1097/01.blo.0000141493.52166.69 15346057 · DOI
  35. [37]American Joint Committee on Cancer AJCC Cancer Staging Manual 2010 7 New York Dordrecht Heidelberg London Springer 279 290
  36. [38]Munshi NC, Longo DL, Anderson KC (2011) Plasma Cell Disorders. In: Longo D.L., Kasper D.L., Jameson J.L., Fauci A.S., Hauser S.L., Loscalzo J.(eds) Harrison’s Principles of Internal Medicine, 18th edn. McGraw-Hill Professional, pp 936-944
  37. [39]Bacci G Bertoni F Longhi A Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor Cancer 2003 97 12 3068 3075 10.1002/cncr.11456 12784343 · DOI · Paper page
  38. [40]Amit P Patro DK Basu D Elangovan S Parathasarathy V Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas Am J Clin Oncol 2013 23388556
  39. [41]Schmidt GP Schoenberg SO Schmid R Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT Eur Radiol 2007 17 4 939 949 10.1007/s00330-006-0361-8 16951929 · DOI
  40. [42]Rööser B Attewell R Berg NO Rydholm A Survival in soft tissue sarcoma. Prognostic variables identified by multivariate analysis Acta Orthop Scand 1987 58 5 516 522 10.3109/17453678709146391 3425281 · DOI
  41. [43]Vanel D Lacombe MJ Couanet D Kalifa C Spielmann M Genin J Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy Radiology 1987 164 1 243 245 10.1148/radiology.164.1.3588913 3588913 · DOI
  42. [44]Kransdorf MJ, Murphey MD (2014) Imaging of Soft Tissue Tumors, 3rd edn. Lippincott williams & wilkins, pp 542-549
  43. [45]Grey AC Davies AM Mangham DC Grimer RJ Ritchie DA The ‘penumbra sign’ on T1-weighted MR imaging in subacute osteomyelitis: frequency, cause and significance Clin Radiol 1998 53 8 587 92 10.1016/S0009-9260(98)80150-5 9744584 · DOI
  44. [46]Sah PL Sharma R Kandpal H In vivo proton spectroscopy of giant cell tumor of the bone AJR Am J Roentgenol 2008 190 2 W133 139 10.2214/AJR.07.2802 18212197 · DOI

Cited by

Sorted by citations

Authors
Nascimento, D., Suchard, G., Hatem, M., & de Abreu, A.
Affiliations
  • Serviço de Saúde da Região Autónoma da Madeira (PT)
  • Hospital Mãe de Deus (BR)
Corresponding author
Nascimento, Duarte
ORCID
Suchard, Guilherme
Venue
Insights into Imaging
Publisher
Springer Science and Business Media LLC
Published
2014-07-09
Volume
5
Issue
4
Pages
419-440
ISSN
1869-4101 (ISSN-L)
DOI
10.1007/s13244-014-0339-z
PMC
PMC4141345
OpenAlex
W2051182438
Cited by
106
References
0
Citations by year
2026: 11 · 2025: 16 · 2024: 6 · 2023: 16 · 2022: 14 · 2021: 18 · 2020: 9 · 2019: 6 · 2018: 4 · 2017: 3 · 2015: 3
FWCI
1.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Insights into Imaging (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
bone tumors, tumor-like lesions, magnetic resonance imaging, differential diagnosis, bone marrow lesions, local staging, surgical planning, neoadjuvant therapy response, restaging, MRI-guided biopsy, MRI pitfalls

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review